CRP and Stroke: This question will be answered by the Phase III trial, CANTOS, which randomized >10,000 patients with hs-CRP ≥2 mg/l to treatment in a secondary prevention population; the goal is to evaluate the composite primary endpoint of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death 20, 21.